A lawsuit was filed on behalf of investors in Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) shares over alleged securities laws violations.
San Diego, CA -- (SBWIRE) -- 03/19/2019 -- An investor, who purchased shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP), filed a lawsuit against Corbus Pharmaceuticals Holdings over alleged violations of Federal Securities Laws.
Investors who purchased shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
On February 28, 2019, an article was published entitled, "Corbus Has Ties to Suspect Investors And A History Of Failed Clinical Trials for Lenabasum." The article alleges that Corbus Pharmaceuticals Holdings Inc "has ties to investors convicted of or alleged to have committed securities fraud" and that its drug candidate, lenabasum, is believed to have "failed its major trials in [systemic sclerosis] and [cystic fibrosis]."
The plaintiff claims that between November 14, 2016 and February 28, 2019, the Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about its drug candidate Lenabasum.
Those who purchased shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels